MIAMI, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Founded in California in 2008, Amarantus Biosciences, Inc. (OTCBB:AMBS) is now poised to take the biotech world by storm with their proprietary new technology. It’s called Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF, for short. Discovered by combining research conducted at the National Institutes of Health throughout the 1990s, this highly potent protein treatment for diseases caused by cell death (apoptosis) is currently in pre-clinical development. Their first target is Parkinson’s disease.
